PharmaCorp Announces Upsized C$20 Million Bought Deal Public Offering

Executive Summary

• PharmaCorp Rx Inc. entered into an amended bought‑deal agreement with a syndicate led by Canaccord Genuity Corp. and Acumen Capital Finance Partners to sell 47.7 million units at C$0.42 per unit, targeting gross proceeds of approximately C$20.0 million.
• Net proceeds are earmarked for future pharmacy acquisition opportunities and general working‑capital needs.
• The offering includes an over‑allotment option for up to an additional 15% of the units and is expected to close on or about November 12, 2025, subject to regulatory approvals.

Key Details

• Units Offered: 47.7 million units (each unit = 1 common share + ½ warrant).
• Offering Price: C$0.42 per unit.
• Gross Proceeds: Approximately C$20.0 million.
• Warrant Terms: Each whole warrant allows purchase of one common share at an exercise price of C$0.50, exercisable for 24 months from the closing date.
• Use of Proceeds: Funding future pharmacy acquisitions and general working‑capital requirements.
• Closing Date: Expected on or about November 12, 2025, pending completion of documentation and receipt of TSX Venture Exchange and other regulatory approvals.
• Over‑Allotment Option: Up to 15% additional units, common shares, or warrants may be purchased by the underwriters within 30 days after closing for stabilization purposes.
• Prospectus Supplement: Units will be offered via a prospectus supplement attached to the Company’s short‑form base shelf prospectus dated October 14, 2025; filings available on SEDAR+.

Notable Quotes

(No direct quotes were provided in the release.)